Erika Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erika Wong has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Che-Chung Yeh
Department of Anesthesia and Perioperative Care, University of California, San Francisco School of Medicine, San Francisco, CA 94143
1 shared publication Elliot Lloyd
Department of Anesthesia and Perioperative Care, University of California, San Francisco School of Medicine, San Francisco, CA 94143
1 shared publicationFengyun Xu
Department of Anesthesia and Perioperative Care, University of California, San Francisco School of Medicine, San Francisco, CA 94143
1 shared publicationIvana Zlatanova
Cardiovascular Research Institute, University of California, San Francisco School of Medicine, San Francisco, CA 94158; and
1 shared publication- Judith Hellman
Department of Anesthesia and Perioperative Care, UCSF School of Medicine, San Francisco, California, USA
1 shared publication - Jérémie Joffre
Intensive Care Unit, Saint-Antoine University Hospital, APHP, Sorbonne University, Paris, France
1 shared publication
Latest Publications
- Open Access
- 15 June 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 204 (12) , 3339-3350
Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury
Cannabis sativa and its principal components, Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol, are increasingly being used to treat a variety of medical problems, including inflammatory conditions. Although studies suggest that the endocannabinoid system has immunomodulatory properties, there remains a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection and injury. We investigated the effects and mechanism(s) of action of cannabinoid receptor agonists, including Δ9-THC, on inflammation and organ injury in endotoxemic mice. Administration of Δ9-THC caused a dramatic early upregulation of plasma IL-10 levels, reduced plasma IL-6 and CCL-2 levels, led to better clinical status, and attenuated organ injury in endotoxemic mice. The anti-inflammatory effects of Δ9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Δ9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119. Although Δ9-THC administration reduced the activation of several spleen immune cell subsets, the anti-inflammatory effects of Δ9-THC were preserved in splenectomized endotoxemic mice. Finally, using IL-10–GFP reporter mice, we showed that blood monocytic myeloid-derived suppressive cells mediate the Δ9-THC–induced early rise in circulating IL-10. These results indicate that Δ9-THC potently induces IL-10, while reducing proinflammatory cytokines, chemokines, and related organ injury in endotoxemic mice via the activation of CB1R. These data have implications for acute and chronic conditions that are driven by dysregulated inflammation, such as sepsis, and raise the possibility that CB1R-signaling may constitute a novel target for inflammatory disorders. Key Points Δ9-THC increases IL-10 and reduces IL-6 and CCL2 in endotoxemic mice via CB1R. Δ9-THC decreases lung inflammation and organ injury in endotoxemic mice. Monocytic-MDSCs mediate Δ9-THC–induced IL-10 upregulation in endotoxemic mice.
- 15 June 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 204 (12) , 3339-3350
Open AccessActivation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury
Cannabis sativa and its principal components, Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol, are increasingly being used to treat a variety of medical problems, including inflammatory conditions. Although studies suggest that the endocannabinoid system has immunomodulatory properties, there remains a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection and injury. We investigated the effects and mechanism(s) of action of cannabinoid receptor agonists, including Δ9-THC, on inflammation and organ injury in endotoxemic mice. Administration of Δ9-THC caused a dramatic early upregulation of plasma IL-10 levels, reduced plasma IL-6 and CCL-2 levels, led to better clinical status, and attenuated organ injury in endotoxemic mice. The anti-inflammatory effects of Δ9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Δ9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119. Although Δ9-THC administration reduced the activation of several spleen immune cell subsets, the anti-inflammatory effects of Δ9-THC were preserved in splenectomized endotoxemic mice. Finally, using IL-10–GFP reporter mice, we showed that blood monocytic myeloid-derived suppressive cells mediate the Δ9-THC–induced early rise in circulating IL-10. These results indicate that Δ9-THC potently induces IL-10, while reducing proinflammatory cytokines, chemokines, and related organ injury in endotoxemic mice via the activation of CB1R. These data have implications for acute and chronic conditions that are driven by dysregulated inflammation, such as sepsis, and raise the possibility that CB1R-signaling may constitute a novel target for inflammatory disorders. Key Points Δ9-THC increases IL-10 and reduces IL-6 and CCL2 in endotoxemic mice via CB1R. Δ9-THC decreases lung inflammation and organ injury in endotoxemic mice. Monocytic-MDSCs mediate Δ9-THC–induced IL-10 upregulation in endotoxemic mice.